Article Text

Integrating rapid diagnostic testing for congenital CMV into the Newborn Hearing Screening Programme: the audiovestibular physician's perspective
  1. S Kadambari1,
  2. S Walter2,
  3. L Stimson1,
  4. S Luck3,
  5. P D Griffiths4,
  6. M Sharland1
  1. 1 Paediatric Infectious Diseases Research Group, St George's University of London, London, UK
  2. 2 St Helier Hospital, Carshalton, Surrey, UK
  3. 3 Kingston Hospital NHS Foundation Trust, Kingston Upon Thames, Surrey, UK
  4. 4 Department of Virology, Royal Free Hospital, London, UK
  1. Correspondence to Dr S Kadambari, Paediatric Infectious Diseases Research Group, St George's University of London, Cranmer Terrace, London SW17 0RE, UK; skadamba{at}

Statistics from

Congenital cytomegalovirus (cCMV) affects 0.3% of all babies born in the UK and accounts for 20% of all childhood sensorineural hearing loss.1 Samples need to be taken in the first 3 weeks of life to confirm congenital infection. Treatment using oral valganciclovir has been shown in a recent randomised controlled trial to prevent hearing deterioration and improve neurocognitive outcomes when started in the first month of life.2 In the absence of a screening programme, the great majority of affected infants are detected in early childhood when no randomised studies have yet shown treatment to be effective. A multicentre cohort study showed that testing for cCMV in …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.